Browse > Article
http://dx.doi.org/10.22722/KJPM.2021.29.2.95

Pharmacotherapy for Patients Complaining With Somatic Symptoms  

Lee, Kyung-Kyu (Department of Psychiatry, College of Medicine, Dankook University)
Publication Information
Korean Journal of Psychosomatic Medicine / v.29, no.2, 2021 , pp. 95-101 More about this Journal
Abstract
Patients complaining with somatic symptoms are very common in clinical practice, and are often consulted to medical department. But it is difficult to treat well. The treatment of somatic symptom disorder is multi-modal as none of the methods on their own provide a satisfactory outcome. The treatment of somatic symptoms disorders is complicated by lack of boundary, conceptual clarity, and overemphasis on psychosocial causation and effectiveness of psychological treatments. In clinical practice all classes of psychotropics are used to treat somatic symptoms disorder. Drugs such as tricyclic antidepressants, serotonin reuptake inibitors(SSRI), serotonin and noradrenalin reuptake inhibitors (SNRI), atypical antipsychotics are studied. The evidence indicates that these drugs are effective in somatic symptom disorders. All classes of antidepressants seem to be effective against somatic symptom disorders. SSRIs are more effective against hypochondriasis and body dysmorphic disorder, and SNRIs appear to be more effective than other antidepressants when pain is predominant. The author suggest that psychiatrists should know how to treat patients complaining with somatic symptoms by using not only psychotherapeutic approach but also pharmacological treatment. It will be helpful to reduce suffering and increase quality of life of these patients.
Keywords
Somatic symptoms; Somatic symptom disorder; Pharmacotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-36.
2 Muller JE, Wentzel I, Koen L, Niehaus DJH, Seedat S, Stein DJ. Escitalopram in the treatment of multisomatoform disorder: A double-blind placebo-controlled trail. Int Clin Psychopharmacol 2008;23:43-48.   DOI
3 Nagoshi Y, Tominaga T, Fukui K. Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. J Clin Psychopharmacol 2014;34:397-398.   DOI
4 Garcia-Campayo J, Sanz-Carrillo C. Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial. Gen Hosp Psychiatry 2002;24:417-421.   DOI
5 Chesler EJ, Ritchie J, Kokayeff A, Lariviere WR, Wilson SG, Mogil JS. Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 2003;106:325-335.   DOI
6 Fallon BA, Petkova E, Skritskaya N, Sanchez-Lacay A, Schneier F, Vermes D, Cheng J, Liebowitz MR. A doublemasked, placebo-controlled study of fluoxetine for hypochondriasis. J Clin Psychopharmacol 2008;28:638-645.   DOI
7 Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: Different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects-A possible opioid involvement in severe depression. J Mol Neurosci 2002;18:143-149.   DOI
8 Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: Incidence, evaluation, therapy and outcome. Am J Med 1989;86:262-266.   DOI
9 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. Washington, DC: American Psychiatric Publishing;2000.
10 Somashekar B, Jainer A, Wuntakal B. Psychopharmacotherapy of somatic symptoms disorder. Int Rev psychiatry 2013;25:107-115.   DOI
11 Chaturvedi SK, Upadhyaya MP, Rao S. Somatic symptoms in a community clinic. Indian J Psychiatry 1988;30:369-374.
12 Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric co-morbidity and management. Int J Methods Psychiatr Res 2003;12:34-43.   DOI
13 Bass C, Benjamin S. The management of chronic somatisation. Br J Psychiatry 1993;162:472-480.   DOI
14 Bass C, Peveler R, House A. Somatoform disorder: Severe psychiatric illnesses neglected by psychiatrists. Br J Psychiatry 2001;179:11-14.   DOI
15 Fink P, Rosendal M. Recent developments in the understanding and management of functional somatic symptoms in primary care. Curr Opin Psychiatry 2008;21:182-188.   DOI
16 Noyes R Jr, Holt CS, Kathol RG. Somatization. Diagnosis and management. Arch Fam Med 1995;4:790-795.   DOI
17 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Publishing;2013.
18 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization;1992.
19 Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007;69:881-888.   DOI
20 Lee KK. Psychotherapy for patients complaining with somatic symptoms. Psychoanalysis 2013;24:78-85.
21 Altamura AC, DiRosa A, Ermentini A, Guaraldi GP, Invvernizzi G, Rudas N, Tacchini G. Levosulpiride in somatoform disorders: a double blind placebo-controlled cross-over study. Int J Psychiatry Clin Pract 2003;7:155-159.   DOI
22 Fallon BA, Schneier FR, Marshall R, Campeas R, Vermes D, Goetz D, Liebowitz MR. The pharmacotherapy of hypochondriasis. Psychopharmacol Bull 1996;32:607-611.
23 Wesner RB, Noyes R. Imipramine: an effective treatment for illness phobia. J Affect Disord 1991;22:43-48.   DOI
24 Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 1996;11:247-254.   DOI
25 Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-272.   DOI
26 Volz HP, Murck H, Kasper S, Moller HJ. St. John's wort extract (LI160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002;164:294-300.   DOI
27 Kleinstauber M, Witthoft M, Hiller W, Steffanowski A, Lambert M, Meinhardt G, Lieb K. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev 2013;7.
28 Fallon BA. Pharmacotherapy of somatoform disorders. J Psychosom Res 2004;56:455-460.   DOI
29 Trieschmann RB, Stolov WC, Montgomery ED. An approach to the treatment of abnormal ambulation resulting from conversion reaction. Arch Phys Med Rehabil 1970;51:198-206.
30 Noyes R Jr, Happel RL, Muller BA, Holt CS, Kathol RL, Sieren LR, Amos JJ. Fluvoxamine for somatoform disorders: an open trial. Gen Hosp Psychiatry 1998;20:339-344.   DOI
31 Fishbain DA, Cutler RB, Rosomoff HL. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med 1998;60:503-509.   DOI
32 Sussman N. SNRIs versus SSRIs: mechanisms of action in treating depressions and painful physical symptoms. Primary Care Companion J Clin Psychiatry 2003;5:19-26.   DOI
33 Han C, Pae C, Lee B, Ko Y, Masand PS, Patker AA, Patkar AA, Joe S, Jung I. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12 week prospective, open-label, randomized, parallel-group trial. Clin Drug Investig 2008;28:251-261.   DOI
34 Henningsen P. Management of somatic symptom disorder. Dialogues Clin Neurosci 2018;20:23-31.   DOI
35 Phillips KA, Najar F. An open label study of citalopram in body dysmorphic disorder. J Clinl Psychiatry 2003;64:715-720.   DOI
36 Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D. Clomipramine vs desipramine crossover trail in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999;56:1033-1039.   DOI
37 Phillips KA, Albertini RS, Siniscalchi JM, Khan AH, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart -review study. J Clin Psychiatry 2001;62: 721-727.   DOI
38 Nagoshi Y, Tominaga T, Fukui K. Blonanserin augmentation for treatment-resistant somatic symptom disorder: a case series. Clin Neuropharmacol 2016;39:112-114.   DOI
39 Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet 1999;354:936-939.   DOI
40 Stahl SM. Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry 2004;65:460-461.   DOI
41 Delargy MA, Peatfield RC, Burt AA. Successful rehabilitation in conversion paralysis. Br Med J 1986;292:1730-1731.   DOI
42 Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998;59:165-171.   DOI
43 Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002;59:381-388.   DOI
44 Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005;62:903-910.   DOI
45 Garcia-Campayo J, Sanz-Carrillo C. Gabapentin for the treatment of patients with somatization disorder. J Clin Psychiatry 2001;62:474.   DOI
46 Guglielmo R, Martinotti G, Janiri L. Gabapentin as Add-On Treatment for Somatoform Disorder: a Case Report. Clin Neuropharmacol 2012;35:45-46.   DOI
47 Johansen ML, Risor MB. What is the problem with medically unexplained symptoms for GPs? A meta-synthesis of qualitative studies. Patient Educ Couns 2017;100:647-654.   DOI
48 O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained medical symptoms and syndromes. J Fam Pract 1999;48:980-990.
49 Jeffery LJ, Kroenke K. Prevalence, impact and prognosis of multisomatoform disorder in primary care: a 5-year follow-up study. Psychosom Med 2008;70:430-434.   DOI
50 Sumathipala A. What is the evidence for the efficacy of treatment for somatoform disorder? A critical review of previous intervention studies. Psychosom Med 2007;69:889-900.   DOI
51 Muller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St John's wort: a randomized double-blind and placebo-controlled trial. Psychosom Med 2004;66: 538-547.   DOI
52 Harnack D, Scheel M, Mundt A, Kupsch A, Heinz A, Strohle A. Pregabalin in patients with antidepressant treatment-resistant Somatoform disorders-a case series. J Clin Psychopharmacol 2007;27:537-539.   DOI
53 Han C, Pae CU, Lee BH, Ko Y, Masand PS, Patkar AA, Jun I. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:437-444.   DOI
54 Luo Y, Zhang MY, Wu WY, Li CB, Lu Z, Li QW. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1522-1525.   DOI
55 Fallon BA, Liebowitz MR, Salman E, Schneier FR, Jusino C, Hollander E, Klein DF. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol 1993; 13:438-441.
56 Speed J. Behavioral management of conversion disorder: retrospective study. Arch Phys Med Rehabil 1996;77:147-154.   DOI
57 Greeven A, van Balkom AJ, Visser S, Merkelbach JW, van Rood YR, van Dyck R, Van der Does AJW, Zitman FG, Spinhoven P. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry 2007;164:91-99.   DOI
58 Pilowsky L. The response to treatment in hypochondriacal disorders. Aust N Z J Psychiatry 1968;2:88-92.   DOI
59 Magarinos M, Zafar U, Nissenson KK, Blanco C. Epidemiology and treatment of hypochondriasis. CNS Drugs 2002;16:9-22.   DOI